VIR – vir biotechnology, inc. (US:NASDAQ)
Stock Stats
News
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.
Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program [Yahoo! Finance]
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency [Yahoo! Finance]
Form 4 Vir Biotechnology, Inc. For: Nov 15 Filed by: O'Byrne Jason
Form 4 Vir Biotechnology, Inc. For: Nov 06 Filed by: de Verneuil Vanina
Form 144 Vir Biotechnology, Inc. Filed by: de Verneuil Vanina
Form 4 Vir Biotechnology, Inc. For: Nov 01 Filed by: de Verneuil Vanina
Form 144 Vir Biotechnology, Inc. Filed by: de Verneuil Vanina
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.